Summary
Deletion of chromosome arm 1p and amplification of the MYCN oncogene are well-recognized genetic alterations in neuroblastoma cells. Recently, another alteration has been reported; gain of the distal part of chromosome arm 17q. In this study 48 neuroblastoma tumours were successfully analysed for 17q status in relation to known genetic alterations. Chromosome 17 status was detected by fluorescence in situ hybridization (FISH). Thirty-one of the 48 neuroblastomas (65%) showed 17q gain, and this was significantly associated with poor prognosis. As previously reported, 17q gain was significantly associated with metastatic stage 4 neuroblastoma and more frequently detected than both deletion of chromosome arm 1p and MYCN amplification in tumours of all stages. 17q gain also showed a strong correlation to survival probability (P = 0.0009). However, the most significant correlation between 17q gain and survival probability was observed in children with low-stage tumours (stage 1, 2, 3 and 4S), with a survival probability of 100% at 5 years from diagnosis for children with tumours showing no 17q gain compared to 52.5% for those showing 17q gain (P = 0.0021). This suggests that 17q gain as a prognostic factor plays a more crucial role in low-stage tumours. Expression of the somatostatin receptor 2 (SSTR2), localized in chromosome region 17q24, has in previous studies been shown to be positively related to survival in neuroblastoma. A point mutation in the SSTR2 gene has earlier been reported in a human small-cell lung cancer. In this study, mutation screening of the SSTR2 gene in 43 neuroblastoma tumours was carried out with polymerase chain reaction-based single-stranded conformation polymorphism/heteroduplex (SSCP/HD) and DNA sequencing, and none of the tumours showed any aberrations in the SSTR2 gene. These data suggest that mutations in the SSTR2 gene are uncommon in neuroblastoma tumours and do not correlate with either the 17q gain often seen or the reason some tumours do not express SSTR2 receptors. Overall, this study indicates that gain of chromosome arm 17q is the most frequently occurring genetic alteration, and that it is associated with established prognostic factors.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Ambros, PF, Ambros, IM, Strehl, S, Bauer, S, Luegmayr, A, Kavar, H, Ladenstein, R, Fink, FM, Horcher, E & Printz, G et al (1995). Regression and progression in neuroblastoma. Does genetics predict tumour behaviour?. Eur J Cancer 31A: 510–515.
Bell, GI, Yasuda, K, Kong, H, Law, SF, Raynor, K & Reisine, T (1995). Molecular biology of somatostatin receptors. Ciba Found Symp 190: 65–88.
Brodeur, GM (1998). Clinical and biological aspects of neuroblastoma. In:The Genetic Basis of Human Cancer, Vogelstein B, Kinzler KWMcGraw-Hill: New York 691–711.
Brodeur, GM, Pritchard, J, Berthold, F, Carlsen, NL, Castel, V, Castelberry, RP, De Bernardi, B, Evans, AE, Favrot, M & Hedborg, F et al (1993). Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11: 1466–1477.
Caron, H, van Sluis, P, van Roy, N, de Kraker, J, Speleman, F, Voute, PA, Westerveld, A, Slater, R & Veersteg, R (1994). Recurrent 1;17 translocations in human neuroblastoma reveal nonhomologous mitotic recombination during the S/G2 phase as a novel mechanism for loss of heterozygosity. Am J Hum Genet 55: 341–347.
Caron, H, van Sluis, P, van Roy, N, de Kraker, J, Bokkerink, J, Egeler, M, Laureys, G, Slater, R, Westerveld, A, Voute, PA & Versteeg, R (1996). Allelic loss of chromosome 1p as a predictor of unfavourable outcome in patients with neuroblastoma. N Engl J Med 334: 225–230.
Dib, C, Faure, S, Fizames, C, Samson, D, Drouot, N, Vignal, A, Millasseau, P, Marc, S, Hazan, J, Seboun, E, Lathrop, M, Gyapay, G, Morissette, J & Weissenbach, J (1996). A comprehensive genetic map of the human genome based on 5264 microsatellites. Nature 380: 152–154.
Gale, G, D'Angio, G, Uri, A, Chatten, J & Koop, CE (1982). Cancer in neonates: the experience at the children's hospital of Philadelphia. Pediatrics 70: 409–413.
Kogner, P, Borgström, P, Bjellerup, P, Schilling, FH, Refai, E, Jonsson, C, Dominici, C, Wassberg, E, Bihl, H, Jacobsson, H, Theodorsson, E & Hassan, M (1997). Somatostatin in neuroblastoma and ganglioneuroma. Eur J Cancer 33: 2084–2089.
Lastowska, M, Cotterill, S, Pearson, ADJ, Roberts, P, McGuckin, A, Lewis, I & Bown, N (1997a). Gain of chromosome arm 17q predicts unfavorable outcome in neuroblastoma patients. Eur J Cancer 33: 1627–1633.
Lastowska, M, Roberts, P, Pearson, ADJ, Lewis, I, Wolstenholme, J & Bown, N (1997b). Promiscuous translocations of chromosome arm 17q in human neuroblastomas. Genes Chromosomes Cancer 19: 143–149.
Lastowska, M, Van Roy, N, Bown, N, Speleman, F, Lunec, J, Strachan, T, Pearson, ADJ & Jackson, MS (1998). Molecular cytogenetic delineation of 17q translocation breakpoints in neuroblastoma cell lines. Genes Chromosomes Cancer 23: 116–122.
Look, AT, Hayes, FA, Shuster, JJ, Douglass, EC, Castleberry, RP, Bowman, LC, Smith, EI & Brodeur, GM (1991). J Clin Oncol 9: 581–591.
Martinsson, T, Sjöberg, RM, Hedborg, F & Kogner, P (1995). Deletion of 1p loci and microsatellite instability in neuroblastomas analyzed with short-tandem repeat polymorphism. Cancer Res 55: 5681–5686.
Martinsson, T, Sjöberg, RM, Hallstensson, K, Nordling, M, Hedborg, F & Kogner, P (1997). Delimitation of a critical tumor suppressor region at distal 1p in neuroblastoma tumors. Eur J Cancer 33: 1997–2001.
Meddeb, M, Danglot, G, Chudoba, I, Vénaut, AM, Bénard, J, Avet-Loiseau, H, Vasseur, B, Le Paslier, D, Terrier-Lacombe, MJ, Hartmann, O & Bernheim, A (1996). Additional copies of a 25 Mb chromosomal region originating from 17q23.1–17qter are present in 90% of high-grade neuroblastomas. Genes Chromosomes Cancer 17: 156–165.
Patel, YC, Greenwood, MT, Kent, G, Panetta, R & Srikant, CB (1993). Multiple gene transcripts of the somatostatin receptor SSTR2: Tissue selective distribution and cAMP regulation. Biochem Biophys Res Commun 192: 288–294.
Patel, YC, Greenwood, MT, Panetta, R, Demchyshyn, L, Niznik, H & Srikant, CB (1995). The somatostatin receptor family. Life Sci 57: 1249–1265.
Plantaz, D, Mohapatra, G, Matthay, KK, Pellarin, M, Seeger, RC & Feuerenstein, BG (1997). Gain of chromosome 17 is the most frequent abnormality detected in neuroblastoma by comparative genomic hybridization. Am J Pathol 150: 81–89.
Schilling, FH, Ambros, PF, Bihl, H, Martinsson, T, Ambros, IM, Borgström, P, Jacobsson, H, Falkmer, UG, Treuner, J & Kogner, P (1998). Somatostatin receptor expression in vivo is absent in neuroblastomas showing distal deletion of chromosome 1p and di/tetraploid DNA content. Eur J Cancer, (in press)
Seeger, RC, Brodeur, GM, Sather, H, Dalton, A, Siegel, SE, Wong, KY & Hammond, D (1985). Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N Eng J Med 313: 1111–1116.
Sestini, R, Orlando, C, Peri, A, Tricarico, C, Pazzagli, M, Serio, M, Pagani, A, Bussolati, G, Ganchi, S & Maggi, M (1996). Quantitation of somatostatin receptor type 2 gene expression in neuroblastoma cell lines and primary tumors using competitive reverse transcription-polymerase chain reaction. Clin Cancer Res 2: 1757–1765.
Vandesompele, J, Van Roy, N, Van Gele, M, Laureys, G, Ambros, P, Heimann, P, Devalck, C, Schuuring, E, Brock, P, Otten, J, Gyselinck, J, De Paepe, A & Speleman, F (1998). Genetic heterogeneity of neuroblastoma studied by comparative genomic hybridization. Genes Chromosomes Cancer 23: 141–152.
Van Roy, N, Laureys, G, Cheng, NG, Willem, P, Opdenakker, G, Versteeg, R & Speleman, F (1994). 1;17 translocations and other chromosome 17 rearrangements in human primary tumor neuroblastoma tumors and cell lines. Genes Chromosomes Cancer 10: 103–114.
Yamada, Y, Post, SR, Wang, K, Tager, HS, Bell, GI & Seino, S (1992). Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastronal tract, and kidneys. Proc Natl Acad Sci USA 89: 251–255.
Zhang, CY, Yokogoshi, Y, Yoshimoto, K, Fujinaka, Y, Matsumoto, K & Saito, S (1995). Point mutation of the somatostatin receptor 2 gene in the human small cell lung cancer cell line COR-L103. Biochem Biophys Res Commun 210: 805–815.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Abel, F., Ejeskär, K., Kogner, P. et al. Gain of chromosome arm 17q is associated with unfavourable prognosis in neuroblastoma, but does not involve mutations in the somatostatin receptor 2 (SSTR2) gene at 17q24. Br J Cancer 81, 1402–1409 (1999). https://doi.org/10.1038/sj.bjc.6692231
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6692231
Keywords
This article is cited by
-
SNHG25 facilitates SNORA50C accumulation to stabilize HDAC1 in neuroblastoma cells
Cell Death & Disease (2022)
-
An ALYREF-MYCN coactivator complex drives neuroblastoma tumorigenesis through effects on USP3 and MYCN stability
Nature Communications (2021)
-
Biomarkers in Neuroblastoma: An Insight into Their Potential Diagnostic and Prognostic Utilities
Current Treatment Options in Oncology (2021)
-
NDPKA is not just a metastasis suppressor – be aware of its metastasis-promoting role in neuroblastoma
Laboratory Investigation (2018)
-
Assessment of fine needle aspiration cytology samples for molecular genetic analysis in neuroblastoma
Pediatric Surgery International (2013)